141 related articles for article (PubMed ID: 38779355)
21. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
[TBL] [Abstract][Full Text] [Related]
22. Liver graft injury caused by de novo donor-specific HLA antibodies in pediatric liver transplant recipients with low, moderate, and high immunologic risk.
Liu W; Wang ZL; Kang ZY; Xiao YL; Liu C; Li DH
Am J Surg; 2023 Feb; 225(2):275-281. PubMed ID: 36116972
[TBL] [Abstract][Full Text] [Related]
23. High tacrolimus intra-patient variability is associated with graft rejection, and
Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Hebral AL; Bellière J; Kamar N
World J Gastroenterol; 2018 Apr; 24(16):1795-1802. PubMed ID: 29713132
[TBL] [Abstract][Full Text] [Related]
24. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of current strategies for surveillance and management of donor-specific antibodies: Single-center study.
Sullivan D; Ahn C; Gao A; Lacelle C; Torres F; Bollineni S; Banga A; Mullins J; Mohanka M; Ring S; Wait M; Peltz M; Duddupudi P; Surapaneni D; Kaza V
Clin Transplant; 2018 Jul; 32(7):e13285. PubMed ID: 29774598
[TBL] [Abstract][Full Text] [Related]
26. Predictors of graft failure after first detection of de novo donor-specific HLA antibodies in kidney transplant recipients.
López Del Moral C; Wu K; Naik M; Osmanodja B; Akifova A; Lachmann N; Stauch D; Hergovits S; Choi M; Bachmann F; Halleck F; Schrezenmeier E; Schmidt D; Budde K
Nephrol Dial Transplant; 2023 Dec; 39(1):84-94. PubMed ID: 37410616
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
[TBL] [Abstract][Full Text] [Related]
28. The detrimental impact of persistent vs an isolated occurrence of de novo donor-specific antibodies on intermediate-term renal transplant outcomes.
Loucks-DeVos JM; Eagar TN; Gaber AO; Patel SJ; Teeter LD; Graviss EA; Knight RJ
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28582797
[TBL] [Abstract][Full Text] [Related]
29. Impact of persistent preformed and de novo donor-specific antibodies detected at 1 year after kidney transplantation on long-term graft survival in Japan: a retrospective study.
Fujiyama N; Satoh S; Saito M; Numakura K; Inoue T; Yamamoto R; Saito T; Kanda S; Narita S; Mitobe Y; Habuchi T
Clin Exp Nephrol; 2019 Dec; 23(12):1398-1406. PubMed ID: 31493185
[TBL] [Abstract][Full Text] [Related]
30. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
[TBL] [Abstract][Full Text] [Related]
31. De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection.
Chemouny JM; Suberbielle C; Rabant M; Zuber J; Alyanakian MA; Lebreton X; Carmagnat M; Pinheiro N; Loupy A; Van Huyen JP; Timsit MO; Charron D; Legendre C; Anglicheau D
Transplantation; 2015 May; 99(5):965-72. PubMed ID: 25340597
[TBL] [Abstract][Full Text] [Related]
32. Racial differences in the development of de-novo donor-specific antibodies and treated antibody-mediated rejection after heart transplantation.
Cole RT; Gandhi J; Bray RA; Gebel HM; Yin M; Shekiladze N; Young A; Grant A; Mahoney I; Laskar SR; Gupta D; Bhatt K; Book W; Smith A; Nguyen D; Vega JD; Morris AA
J Heart Lung Transplant; 2018 Apr; 37(4):503-512. PubMed ID: 29198929
[TBL] [Abstract][Full Text] [Related]
33. Antibody-Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor-Specific Antibody Characteristics.
Roux A; Bendib Le Lan I; Holifanjaniaina S; Thomas KA; Hamid AM; Picard C; Grenet D; De Miranda S; Douvry B; Beaumont-Azuar L; Sage E; Devaquet J; Cuquemelle E; Le Guen M; Spreafico R; Suberbielle-Boissel C; Stern M; Parquin F;
Am J Transplant; 2016 Apr; 16(4):1216-28. PubMed ID: 26845386
[TBL] [Abstract][Full Text] [Related]
34. Renal transplant outcomes and de novo donor-specific anti-human leukocyte antigen antibodies: a systematic review.
Sharma A; Lewis JR; Lim WH; Palmer S; Strippoli G; Chapman JR; Alexander SI; Craig JC; Wong G
Nephrol Dial Transplant; 2018 Aug; 33(8):1472-1480. PubMed ID: 29660004
[TBL] [Abstract][Full Text] [Related]
35. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.
Wiebe C; Gibson IW; Blydt-Hansen TD; Karpinski M; Ho J; Storsley LJ; Goldberg A; Birk PE; Rush DN; Nickerson PW
Am J Transplant; 2012 May; 12(5):1157-67. PubMed ID: 22429309
[TBL] [Abstract][Full Text] [Related]
36. Post-transplant de novo non donor-specific HLA antibodies are not associated with poor graft outcome in non-sensitized pediatric recipients of kidney transplantation.
Cioni M; Comoli P; Tagliamacco A; Innocente A; Basso S; Fontana I; Magnasco A; Trivelli A; Nocco A; Macchiagodena M; Catenacci L; Klersy C; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Nocera A
Transpl Immunol; 2021 Apr; 65():101375. PubMed ID: 33610675
[TBL] [Abstract][Full Text] [Related]
37. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
38. Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric Study.
Bertrand D; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Galinier A; Laurent C; Etienne I; Farce F; François A; Guerrot D
Transplantation; 2020 Aug; 104(8):1726-1737. PubMed ID: 32732853
[TBL] [Abstract][Full Text] [Related]
39. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
40. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
